Skip to main content
AI Market Summary
Loading market intelligence...

ACCURAY INC (ARAY) Stock Forecast 2025 - AI Price Prediction & Analysis


ACCURAY INC (ARAY) AI Stock Price Forecast & Investment Analysis

ACCURAY INC Stock Price Chart and Technical Analysis

Loading ACCURAY INC interactive price chart and technical analysis...

ACCURAY INC (ARAY) - Comprehensive Stock Analysis & Investment Research

Deep dive into ACCURAY INC's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about ACCURAY INC, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For ACCURAY INC: ACCURAY INC operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

ACCURAY INC (Stock Symbol: ARAY) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 1122 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing ACCURAY INC's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For ACCURAY INC: With $436M in annual revenue and -26.4% net margin, the company demonstrates developing profitability.

Annual Revenue: $436 million generating a -26.4% net profit margin .

Market Capitalization: $112 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -20.0% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for ACCURAY INC stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For ACCURAY INC: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for ACCURAY INC stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: ACCURAY INC's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For ACCURAY INC: Strong free cash flow generation demonstrates developing operational efficiency.

ACCURAY INC strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company demonstrates robust operational efficiency through strong free cash flow generation of $4 million annually.

The company maintains a healthy 24.3% gross margin, indicating strong pricing power and operational efficiency.

ACCURAY INC (ARAY) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for ACCURAY INC stock analysis.

Loading ACCURAY INC comprehensive fundamental analysis and insider trading data...

Deep dive into ACCURAY INC's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if ACCURAY INC stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For ACCURAY INC: With a P/E ratio of -9.88, the market sees the stock as potentially undervalued.

P/E Ratio -9.88x
P/B Ratio 1.81x
Market Cap $112M
EPS $-0.01
Book Value/Share $0.55
Revenue/Share $3.85
FCF/Share $0.53
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently ACCURAY INC converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For ACCURAY INC: An ROE of -20.0% indicates room for improvement in shareholder value creation.

ROE -20.0%
ROA -2.7%
ROIC -4.8%
Gross Margin 24.3%
Operating Margin -24.6%
Net Margin -26.4%
EBT Margin -2.6%
Tax Rate 32.7%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess ACCURAY INC's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For ACCURAY INC: A current ratio of 1.72 shows adequate liquidity.

Current Ratio 1.72x
Quick Ratio 0.93x
D/E Ratio 3.59x
Financial Leverage 9.10x
Interest Coverage 0.7x
Working Capital $160M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal ACCURAY INC's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For ACCURAY INC: Free cash flow of $4M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $8M
Free Cash Flow $4M
Capital Spending $-4M
FCF/Sales 1.0%
CapEx/Sales 1.0%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively ACCURAY INC uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For ACCURAY INC: An asset turnover of 0.90x suggests room for improvement in asset utilization.

Asset Turnover 0.90x
Receivables Turnover 5.4x
Inventory Turnover 2.0x
Fixed Assets Turnover 13.0x
Days Sales Outstanding 67 days
Days Inventory 185 days
Payables Period 34 days
Cash Conversion Cycle 219 days
Understanding Financial Statement Data

What these metrics mean: Key figures from ACCURAY INC's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For ACCURAY INC: With annual revenue of $436M, ACCURAY INC demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $436M
Operating Income $-98M
Net Income $-106M
R&D Expense $82M
SG&A Expense $21M
Cost of Goods Sold $261M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 74%
Cash & Short-term Investments 21%
Total Liabilities 89%
Short-term Debt 2%
Accounts Receivable 19%
Inventory 29%
Dividend & Shareholder Information
Shares Outstanding 113M

Latest ACCURAY INC Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting ACCURAY INC (ARAY) stock price and investment outlook.

, source: Fierce Healthcare

SUNNYVALE, Calif., July 16, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that they have signed a definitive agreement to acquire ...

, source: Nasdaq

Accuray Inc. ARAY recently announced the receipt of 510(k) clearance for its ClearRT Helical kVCT imaging for the Radixact treatment delivery system from the FDA. This latest development is expected ...

, source: MarketWatch

Accuray Inc. Annual cash flow by MarketWatch. View ARAY net cash flow, operating cash flow, operating expenses and cash dividends.

, source: Yahoo Finance

Earnings call Accuray reported Q3 FY25 revenue of $113M, up 12% YoY, with adjusted EBITDA rising to $6M from $1.1M. Despite China tariff headwinds, management maintained full-year EBITDA guidance and ...

, source: MarketWatch

Visit a quote page and your recently viewed tickers will be displayed here. Sandeep Chalke is currently the Chief Commercial Officer & Senior Vice President at Accuray, Inc. Prior to this, he served ...

, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

ACCURAY INC Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of ACCURAY INC against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $14M x 1.6x
AEMD Unlock Forecast - 30 Days FREE Trial $10M -0.1x 1.7x
ALUR Unlock Forecast - 30 Days FREE Trial $13M -0.4x -0.3x
AMIX Unlock Forecast - 30 Days FREE Trial $2M x 0.3x
ANGO Unlock Forecast - 30 Days FREE Trial $555M -1.4x 3.1x
ANIK Unlock Forecast - 30 Days FREE Trial $138M -4.3x 0.9x
AORT Unlock Forecast - 30 Days FREE Trial $2092M -198.2x 4.8x
APYX Unlock Forecast - 30 Days FREE Trial $149M -3.5x 25.5x
ARAY Unlock Forecast - 30 Days FREE Trial $112M -9.9x 1.8x
ATEC Unlock Forecast - 30 Days FREE Trial $2974M -7.4x 258.4x
ATRC Unlock Forecast - 30 Days FREE Trial $2059M -39.6x 4.3x
AVHHL Unlock Forecast - 30 Days FREE Trial $24M x x
BAX Unlock Forecast - 30 Days FREE Trial $9843M -94.9x 1.4x
BBNX Unlock Forecast - 30 Days FREE Trial $1289M x 4.4x
BDX Unlock Forecast - 30 Days FREE Trial $57959M 34.5x 2.3x
BEAT Unlock Forecast - 30 Days FREE Trial $27M -5.7x 67.6x
BJDX Unlock Forecast - 30 Days FREE Trial $2M -0.5x 0.5x
BSX Unlock Forecast - 30 Days FREE Trial $138315M 49.4x 5.9x
BTCY Unlock Forecast - 30 Days FREE Trial $13M -2.7x -0.1x
BVS Unlock Forecast - 30 Days FREE Trial $526M 67.2x 3.2x
CARL Unlock Forecast - 30 Days FREE Trial $132M x 1.2x
CERS Unlock Forecast - 30 Days FREE Trial $412M -13.8x 6.7x
CLPT Unlock Forecast - 30 Days FREE Trial $367M -23.5x 23.1x
CODX Unlock Forecast - 30 Days FREE Trial $18M -0.7x 0.5x
CTSO Unlock Forecast - 30 Days FREE Trial $46M -1.8x 5.1x
CVRX Unlock Forecast - 30 Days FREE Trial $221M -5.5x 4.6x
DCTH Unlock Forecast - 30 Days FREE Trial $368M 306.9x 3.2x
DHAI Unlock Forecast - 30 Days FREE Trial $0M x -0.3x
DRIO Unlock Forecast - 30 Days FREE Trial $549M 0.6x 7.3x
DRTS Unlock Forecast - 30 Days FREE Trial $432M x 5.0x
DXCM Unlock Forecast - 30 Days FREE Trial $26114M 36.2x 9.6x
DYNT Unlock Forecast - 30 Days FREE Trial $1M -0.2x 0.2x
EBRCZ Unlock Forecast - 30 Days FREE Trial $315M x 8.2x
ECIA Unlock Forecast - 30 Days FREE Trial $2M x 1.0x
EMBC Unlock Forecast - 30 Days FREE Trial $707M 7.4x -0.8x
EMED Unlock Forecast - 30 Days FREE Trial $0M x x
FEMY Unlock Forecast - 30 Days FREE Trial $42M -1.4x 9.1x
FOFA Unlock Forecast - 30 Days FREE Trial $8M x 10.0x
GCTK Unlock Forecast - 30 Days FREE Trial $5M 0.9x 2.0x
GIPL Unlock Forecast - 30 Days FREE Trial $5M x 25.8x
GKOS Unlock Forecast - 30 Days FREE Trial $6248M -46.3x 8.1x
GMED Unlock Forecast - 30 Days FREE Trial $11897M 28.1x 2.7x
GUTS Unlock Forecast - 30 Days FREE Trial $122M x 13.8x
HAE Unlock Forecast - 30 Days FREE Trial $3903M 23.2x 4.6x
HRGN Unlock Forecast - 30 Days FREE Trial $32M x 20.4x
IART Unlock Forecast - 30 Days FREE Trial $1063M 200.2x 1.0x
ICCM Unlock Forecast - 30 Days FREE Trial $40M x 13.9x
ICU Unlock Forecast - 30 Days FREE Trial $12M -1.1x 1.1x
ICUI Unlock Forecast - 30 Days FREE Trial $3634M -49.8x 1.7x
IDXG Unlock Forecast - 30 Days FREE Trial $5M 1.0x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $27M x 6.2x
IINNW Unlock Forecast - 30 Days FREE Trial $7M x 1.7x
INBS Unlock Forecast - 30 Days FREE Trial $7M -0.3x 1.8x
INFU Unlock Forecast - 30 Days FREE Trial $181M 32.7x 3.3x
INSP Unlock Forecast - 30 Days FREE Trial $3797M 85.2x 5.7x
IRMD Unlock Forecast - 30 Days FREE Trial $1239M 58.5x 12.6x
IRTC Unlock Forecast - 30 Days FREE Trial $5437M -20.2x 44.6x
KIDS Unlock Forecast - 30 Days FREE Trial $414M -20.7x 1.2x
KMTS Unlock Forecast - 30 Days FREE Trial $1279M x x
KRMD Unlock Forecast - 30 Days FREE Trial $268M -19.8x 16.3x
LMAT Unlock Forecast - 30 Days FREE Trial $1910M 35.8x 5.0x
LNSR Unlock Forecast - 30 Days FREE Trial $134M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $135M -0.6x 5.2x
LUNG Unlock Forecast - 30 Days FREE Trial $83M -4.3x 1.4x
LYRA Unlock Forecast - 30 Days FREE Trial $7M -0.1x 4.6x
MBOT Unlock Forecast - 30 Days FREE Trial $92M -1.3x 1.2x
MCAG Unlock Forecast - 30 Days FREE Trial $33M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $31M x -9.9x
MDAI Unlock Forecast - 30 Days FREE Trial $45M -1.3x -42.3x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.2x 12.2x
MDXG Unlock Forecast - 30 Days FREE Trial $1062M 26.0x 4.4x
MGRM Unlock Forecast - 30 Days FREE Trial $217M -10.7x 25.1x
MHUA Unlock Forecast - 30 Days FREE Trial $226M x 1.4x
MMM Unlock Forecast - 30 Days FREE Trial $89724M 26.4x 19.4x
MMSI Unlock Forecast - 30 Days FREE Trial $5140M 43.4x 3.4x
MODD Unlock Forecast - 30 Days FREE Trial $28M -2.1x 3.2x
NEPH Unlock Forecast - 30 Days FREE Trial $60M 40.5x 7.2x
NMTC Unlock Forecast - 30 Days FREE Trial $26M -1.7x 3.2x
NPCE Unlock Forecast - 30 Days FREE Trial $543M -10.4x 29.3x
NSPR Unlock Forecast - 30 Days FREE Trial $79M -4.3x 1.2x
NUMD Unlock Forecast - 30 Days FREE Trial $2M x x
NVCR Unlock Forecast - 30 Days FREE Trial $1530M -20.8x 4.5x
NXGL Unlock Forecast - 30 Days FREE Trial $12M -6.8x 2.4x
OBIO Unlock Forecast - 30 Days FREE Trial $255M -3.4x 2.6x
ODYY Unlock Forecast - 30 Days FREE Trial $4M x x
OFIX Unlock Forecast - 30 Days FREE Trial $611M -5.8x 1.4x
OSRH Unlock Forecast - 30 Days FREE Trial $17M x 0.2x
OSUR Unlock Forecast - 30 Days FREE Trial $180M 17.1x 0.5x
PAVM Unlock Forecast - 30 Days FREE Trial $8M 2.5x 0.2x
PDEX Unlock Forecast - 30 Days FREE Trial $131M 11.7x 3.2x
PEN Unlock Forecast - 30 Days FREE Trial $12247M 74.7x 9.0x
PETV Unlock Forecast - 30 Days FREE Trial $36M -1.4x 8.6x
PLRZ Unlock Forecast - 30 Days FREE Trial $61M x 3.3x
PLSE Unlock Forecast - 30 Days FREE Trial $975M -2.6x 10.5x
PMI Unlock Forecast - 30 Days FREE Trial $22M x 2.8x
PODD Unlock Forecast - 30 Days FREE Trial $21377M 86.8x 15.5x
PRCT Unlock Forecast - 30 Days FREE Trial $2013M -45.4x 5.3x
PROF Unlock Forecast - 30 Days FREE Trial $221M x 6.9x
PSTV Unlock Forecast - 30 Days FREE Trial $16M -0.3x 3.2x
PYPD Unlock Forecast - 30 Days FREE Trial $24M x 1.2x
RCEL Unlock Forecast - 30 Days FREE Trial $107M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $33M x 15.0x
RMD Unlock Forecast - 30 Days FREE Trial $36816M 25.6x 6.0x
RSMDF Unlock Forecast - 30 Days FREE Trial $3977M 2.8x 0.7x
RTGN Unlock Forecast - 30 Days FREE Trial $60M x x
RVP Unlock Forecast - 30 Days FREE Trial $25M -0.9x 0.3x
SGHT Unlock Forecast - 30 Days FREE Trial $429M -3.7x 6.7x
SIBN Unlock Forecast - 30 Days FREE Trial $811M -14.3x 4.7x
SIGY Unlock Forecast - 30 Days FREE Trial $3M x x
SKIN Unlock Forecast - 30 Days FREE Trial $178M -1.8x 2.7x
SNOA Unlock Forecast - 30 Days FREE Trial $6M -5.6x 1.5x
SNWV Unlock Forecast - 30 Days FREE Trial $272M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $14392M 9.4x 2.9x
SRTS Unlock Forecast - 30 Days FREE Trial $64M 31.6x 1.3x
SSKN Unlock Forecast - 30 Days FREE Trial $7M -8.0x 5.7x
STIM Unlock Forecast - 30 Days FREE Trial $92M -1.0x 3.4x
STME Unlock Forecast - 30 Days FREE Trial $14M x x
STSS Unlock Forecast - 30 Days FREE Trial $68M -2.5x 0.2x
SYK Unlock Forecast - 30 Days FREE Trial $136856M 46.5x 11.7x
TCMD Unlock Forecast - 30 Days FREE Trial $623M 34.3x 3.0x
TELA Unlock Forecast - 30 Days FREE Trial $46M -1.8x 29.8x
TFX Unlock Forecast - 30 Days FREE Trial $5679M 31.0x 1.5x
TLSI Unlock Forecast - 30 Days FREE Trial $368M -3.6x -5.6x
TLSIW Unlock Forecast - 30 Days FREE Trial $62M x -1.9x
TMCI Unlock Forecast - 30 Days FREE Trial $173M -7.5x 1.9x
TNDM Unlock Forecast - 30 Days FREE Trial $1421M -17.1x 10.7x
TNON Unlock Forecast - 30 Days FREE Trial $10M -0.3x 2.0x
UFPT Unlock Forecast - 30 Days FREE Trial $1657M 24.7x 4.1x
USAQ Unlock Forecast - 30 Days FREE Trial $3M x x
UTMD Unlock Forecast - 30 Days FREE Trial $179M 15.4x 1.5x
VERO Unlock Forecast - 30 Days FREE Trial $4M 0.0x 1.3x
VYCO Unlock Forecast - 30 Days FREE Trial $7M x x
WST Unlock Forecast - 30 Days FREE Trial $19238M 39.1x 6.3x
XAIR Unlock Forecast - 30 Days FREE Trial $99M -0.3x 7.8x
XTNT Unlock Forecast - 30 Days FREE Trial $87M 49.6x 1.7x

Frequently Asked Questions - ACCURAY INC Stock Forecast

How accurate are ACCURAY INC stock predictions?

Our AI model shows a 33% Spearman correlation coefficient for ARAY predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence ACCURAY INC stock price forecasts?

Our analysis considers ACCURAY INC's financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is ACCURAY INC a good investment in 2025?

Based on our AI analysis, ACCURAY INC shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are ACCURAY INC forecasts updated?

ACCURAY INC stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced ACCURAY INC Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for ACCURAY INC stock.

My Portfolio

Investment Dashboard

Loading your portfolio...